Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.
Stephen J GreeneIyanuoluwa AyodeleJacob B PierceMuhammad Shahzeb KhanSabra C LewseyClyde W YancyBrooke AlhantiHarriette G C Van SpallLarry A AllenGregg C FonarowPublished in: JACC. Heart failure (2024)
In this nationwide U.S. cohort of patients hospitalized for newly diagnosed HFrEF, >4 of 5 patients were projected as eligible for quadruple therapy at discharge; yet, <1 in 6 were prescribed it. If clinical trial benefits can be fully realized, in-hospital initiation of quadruple medical therapy for newly diagnosed HFrEF would yield large absolute reductions in mortality.
Keyphrases
- newly diagnosed
- heart failure
- clinical trial
- helicobacter pylori
- healthcare
- ejection fraction
- helicobacter pylori infection
- prognostic factors
- stem cells
- emergency department
- randomized controlled trial
- type diabetes
- mesenchymal stem cells
- cardiovascular disease
- left ventricular
- patient reported outcomes
- study protocol
- atrial fibrillation
- sensitive detection